1:32 PM
 | 
Oct 12, 2017
 |  BC Extra  |  Company News

Lilly's Verzenio gets Priority Review for label expansion

Eli Lilly and Co. (NYSE:LLY) said FDA accepted and granted Priority Review to an NDA for Verzenio abemaciclib as a first-line endocrine therapy in combination with an aromatase inhibitor to treat hormone receptor-positive, HER2-negative advanced or...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >